Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus PROMETH PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus PROMETH PLAIN.
PHENERGAN VC vs PROMETH PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine